Home » Clinical Trials » Dementia
Study of Depakote for Behavioral and Psychological Symptoms in Dementia
Official Title: An Open-Label Prospective Study of Depakote for Behavioral and Psychological Symptoms in Dementia (BPSD): Use Alone and in Co-Prescription With Atypical Antipsychotic Medications
This prospective, naturalistic, open label study will test the hypothesis that Depakote is
correlated with a reduction in elevated Cohen-Mansfield Agitation Index (CMAI) verbal and
physical agitation and aggression scales over a 6-week period among patients with elevated
scores on those scales, and that these positive results can be achieved with fewer side
effects than with other agents. In addition, patients will be rated with respect to changes
in the Clinical Global Impression (CGI) at baseline, week 1, 3, and 6 and the
Neuropsychiatric Inventory (NPI) at baseline and week 6.
Phase: Phase 1
Sponsor: Hearthstone Alzheimer Care
Joan Hyde, Ph.D.
||Hearthstone at Golden Pond
Mark Vanelli, MD
Date Last Changed: August 10, 2006